Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns “Speculative Buy” Rating from Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

Anebulo Pharmaceuticals Trading Down 1.3 %

Anebulo Pharmaceuticals stock opened at $1.50 on Tuesday. Anebulo Pharmaceuticals has a 12 month low of $1.25 and a 12 month high of $3.30. The stock’s 50 day simple moving average is $1.88 and its two-hundred day simple moving average is $2.09. The firm has a market cap of $38.90 million, a PE ratio of -5.00 and a beta of -1.00.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.08. On average, equities research analysts forecast that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.